Immunophenotype predicts outcome in pediatric acute liver failure

Area of Science:

• Immunology
• Hepatology
• Pediatric Critical Care

Background:

• Pediatric acute liver failure (PALF) is a severe condition with high mortality.
• Immune system dysregulation plays a role in PALF progression and outcomes.
• Identifying biomarkers for risk stratification is crucial for timely intervention.

Purpose of the Study:

• To investigate T-cell immune activation markers, particularly soluble interleukin 2 receptor alpha (sIL2Rα), as predictors of outcome in pediatric acute liver failure.
• To assess the potential of sIL2Rα levels for identifying patients who may benefit from immunomodulatory therapies.

Main Methods:

• Analysis of immune activation markers in 77 pediatric acute liver failure patients from a multinational study.
• Outcomes assessed included survival with native liver, liver transplantation (LT), and death within 21 days.
• Serum sIL2Rα levels were measured and normalized for comparison across outcome groups.

Main Results:

• Normalized serum sIL2Rα levels were significantly higher in patients who died or underwent LT compared to those who survived with their native liver.
• All 37 patients with normal sIL2Rα levels survived, with most retaining their native liver.
• Among 15 patients with markedly high sIL2Rα levels (≥5000 IU/mL), outcomes included survival, death, and LT.

Conclusions:

• Elevated sIL2Rα levels indicate immune activation and are associated with poorer outcomes in pediatric acute liver failure.
• Higher sIL2Rα levels predict an increased likelihood of death or LT within 21 days.
• Identifying patients with high sIL2Rα levels can guide targeted clinical trials for immunomodulatory treatments.